CenterBook Partners LP Lowers Position in Charles River Laboratories International, Inc. (NYSE:CRL)

CenterBook Partners LP reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 45.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,025 shares of the medical research company's stock after selling 11,593 shares during the quarter. CenterBook Partners LP's holdings in Charles River Laboratories International were worth $2,111,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in CRL. Rothschild Investment LLC boosted its stake in Charles River Laboratories International by 480.0% in the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after purchasing an additional 144 shares in the last quarter. Optiver Holding B.V. purchased a new position in Charles River Laboratories International in the 4th quarter worth about $37,000. HM Payson & Co. purchased a new position in Charles River Laboratories International in the 1st quarter worth about $31,000. GeoWealth Management LLC raised its position in Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after buying an additional 190 shares during the last quarter. Finally, Pilgrim Partners Asia Pte Ltd purchased a new position in Charles River Laboratories International in the 4th quarter worth about $48,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on CRL shares. Mizuho reduced their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a report on Wednesday, April 9th. Wall Street Zen lowered shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a report on Saturday, July 5th. Barclays increased their target price on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a report on Thursday, May 8th. TD Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price for the company in a report on Wednesday, May 14th. Finally, Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $174.54.

Insiders Place Their Bets

In related news, EVP Joseph W. Laplume sold 500 shares of Charles River Laboratories International stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the sale, the executive vice president owned 19,513 shares of the company's stock, valued at $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Trading Down 1.4%

CRL traded down $2.15 during trading on Friday, reaching $154.55. The company had a trading volume of 493,642 shares, compared to its average volume of 1,037,944. The stock has a market cap of $7.59 billion, a P/E ratio of -237.77, a PEG ratio of 5.23 and a beta of 1.49. The business has a 50 day simple moving average of $147.42 and a 200-day simple moving average of $150.81. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $254.15. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.78.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The business had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same quarter last year, the firm posted $2.27 earnings per share. The business's revenue was down 2.7% compared to the same quarter last year. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).